These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 9797710)

  • 1. Serum interleukin 1 in ovarian cancer patients.
    Zeisler H; Tempfer C; Joura EA; Sliutz G; Koelbl H; Wagner O; Kainz C
    Eur J Cancer; 1998 May; 34(6):931-3. PubMed ID: 9797710
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Significantly increased interleukin-1A and interleukin-1 soluble type II receptor levels in women with ovarian cancer].
    Kondera-Anasz Z; Mielczarek-Palacz A; Switała J
    Ginekol Pol; 2003 Sep; 74(9):761-6. PubMed ID: 14674121
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum and ascitic fluid levels of interleukin-1, interleukin-6, and tumor necrosis factor-alpha in patients with ovarian epithelial cancer.
    Moradi MM; Carson LF; Weinberg B; Haney AF; Twiggs LB; Ramakrishnan S
    Cancer; 1993 Oct; 72(8):2433-40. PubMed ID: 8402460
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Elevated serum interleukin-37 level is a predictive biomarker of poor prognosis in epithelial ovarian cancer patients.
    Huo J; Hu J; Liu G; Cui Y; Ju Y
    Arch Gynecol Obstet; 2017 Feb; 295(2):459-465. PubMed ID: 27975129
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Serum cytokines in patients with ovarian cancer and benign ovarian cysts].
    Nowak M; Szpakowski M; Malinowski A; Wieczorek A; Maciołek-Blewniewska G; Wilczyński JR; Szpakowski A; Wierzbicka E; Małafiej E; Oszukowski P
    Ginekol Pol; 2001 Dec; 72(12A):1444-8. PubMed ID: 11883294
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum evaluation of interleukin 6 in ovarian cancer patients.
    Tempfer C; Zeisler H; Sliutz G; Haeusler G; Hanzal E; Kainz C
    Gynecol Oncol; 1997 Jul; 66(1):27-30. PubMed ID: 9234916
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum levels of IL-6, IL-8 and CRP as prognostic factors in epithelial ovarian cancer.
    Dobrzycka B; Mackowiak-Matejczyk B; Terlikowska KM; Kulesza-Bronczyk B; Kinalski M; Terlikowski SJ
    Eur Cytokine Netw; 2013; 24(3):106-13. PubMed ID: 24197277
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Monocyte chemoattractant protein-1 serum levels in ovarian cancer patients.
    Hefler L; Tempfer C; Heinze G; Mayerhofer K; Breitenecker G; Leodolter S; Reinthaller A; Kainz C
    Br J Cancer; 1999 Nov; 81(5):855-9. PubMed ID: 10555758
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ascitic interleukin-12 is an independent prognostic factor in ovarian cancer.
    Zeimet AG; Widschwendter M; Knabbe C; Fuchs D; Herold M; Müller-Holzner E; Daxenbichler G; Offner FA; Dapunt O; Marth C
    J Clin Oncol; 1998 May; 16(5):1861-8. PubMed ID: 9586902
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Higher levels of interleukin-6 in cystic fluids from patients with malignant versus benign ovarian tumors correlate with decreased hemoglobin levels and increased platelet counts.
    van der Zee AG; de Cuyper EM; Limburg PC; de Bruijn HW; Hollema H; Bijzet J; Krans M; de Vries EG
    Cancer; 1995 Feb; 75(4):1004-9. PubMed ID: 7842401
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Soluble interleukin-2 receptor alpha is elevated in sera of patients with benign ovarian neoplasms and epithelial ovarian cancer.
    Hurteau JA; Woolas RP; Jacobs IJ; Oram DC; Kurman CC; Rubin LA; Nelson DL; Berchuck A; Bast RC; Mills GB
    Cancer; 1995 Nov; 76(9):1615-20. PubMed ID: 8635066
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Elevation of serum interleukin-1 receptor antagonist levels in women with gynaecological cancers.
    Fujiwaki R; Hata T; Miyazaki K; Kawamura T; Inada K
    Br J Obstet Gynaecol; 1997 Dec; 104(12):1407-8. PubMed ID: 9422021
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum and peritoneal fluid concentrations of soluble human leukocyte antigen, tumor necrosis factor alpha and interleukin 10 in patients with selected ovarian pathologies.
    Sipak-Szmigiel O; Włodarski P; Ronin-Walknowska E; Niedzielski A; Karakiewicz B; Słuczanowska-Głąbowska S; Laszczyńska M; Malinowski W
    J Ovarian Res; 2017 Apr; 10(1):25. PubMed ID: 28376925
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Does vitamin D mediate inhibition of epithelial ovarian cancer by modulating cytokines?
    Mohapatra S; Saxena A; Gandhi G; Koner BC; Singh T; Ray PC
    Clin Transl Oncol; 2015 Aug; 17(8):590-5. PubMed ID: 25740667
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Decreased IL-1 RA concentration in ascites is associated with a significant improvement in overall survival in ovarian cancer.
    Mustea A; Pirvulescu C; Könsgen D; Braicu EI; Yuan S; Sun P; Lichtenegger W; Sehouli J
    Cytokine; 2008 Apr; 42(1):77-84. PubMed ID: 18329282
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of IL-10 in patients with ovarian carcinoma.
    Mustea A; Könsgen D; Braicu EI; Pirvulescu C; Sun P; Sofroni D; Lichtenegger W; Sehouli J
    Anticancer Res; 2006; 26(2C):1715-8. PubMed ID: 16617566
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum and cyst fluid levels of interleukin (IL) -6, IL-8 and tumour necrosis factor-alpha in women with endometriomas and benign and malignant cystic ovarian tumours.
    Daraï E; Detchev R; Hugol D; Quang NT
    Hum Reprod; 2003 Aug; 18(8):1681-5. PubMed ID: 12871882
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum high mobility group box protein 1 as a clinical marker for ovarian cancer.
    Li Y; Tian J; Fu X; Chen Y; Zhang W; Yao H; Hao Q
    Neoplasma; 2014; 61(5):579-84. PubMed ID: 25030441
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Host-tumor interaction in ovarian cancer. Spontaneous release of tumor necrosis factor and interleukin-1 inhibitors by purified cell populations from human ovarian carcinoma in vitro.
    Burger RA; Grosen EA; Ioli GR; Van Eden ME; Brightbill HD; Gatanaga M; DiSaia PJ; Granger GA; Gatanaga T
    Gynecol Oncol; 1994 Nov; 55(2):294-303. PubMed ID: 7959299
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Macrophage colony-stimulating factor as a tumor marker for epithelial ovarian cancer.
    Suzuki M; Ohwada M; Aida I; Tamada T; Hanamura T; Nagatomo M
    Obstet Gynecol; 1993 Dec; 82(6):946-50. PubMed ID: 8233270
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.